不同剂量盐酸氨溴索对慢性阻塞性肺疾病伴呼吸机相关肺部感染患儿炎症介质及血气指标的影响被引量：1

在线阅读下载PDF

导出

摘要目的探讨不同剂量盐酸氨溴索对慢性阻塞性肺疾病(COPD)伴呼吸机相关肺部感染患儿炎症介质及血气指标的影响。方法选择2018年7月至2019年6月医院收治的60例COPD伴呼吸机相关性肺炎患儿,按随机数字表法分为对照组和试验组,各30例。对照组给予15 mg盐酸氨溴索雾化治疗,试验组给予30 mg盐酸氨溴索雾化治疗,治疗2周后,比较两组炎症介质及血气指标。结果治疗后,试验组IL-6为(53.41±18.12)ng/L、TNF-α为(34.36±15.06)ng/L、hs-CRP为(5.33±9.02)g/L,均低于对照组的(73.94±15.89)ng/L、(74.64±18.53)ng/L、(14.32±6.24)g/L,差异均有统计学意义(P<0.05);治疗后,试验组Pa O2为(64.92±5.43)mm Hg,pH为7.43±0.11,均高于对照组的(57.41±5.33)mm Hg、7.30±0.12,试验组PaCO2为(60.11±4.23)mmHg,低于对照组的(63.42±4.24)mmHg,差异均有统计学意义(P<0.05)。结论COPD伴呼吸机相关性肺炎患儿采用大剂量盐酸氨溴索治疗有助于抑制炎症反应,改善血气,减轻痛苦,效果优于常规剂量盐酸氨溴索治疗。

作者江乐川

机构地区江西省都昌县妇幼保健院新生儿科

出处《医疗装备》 2019年第21期116-117,共2页 Medical Equipment

关键词慢性阻塞性肺疾病呼吸机相关性肺炎盐酸氨溴索炎症介质血气指标

分类号 R725.6 [医药卫生—儿科]

引文网络
相关文献

参考文献6

1聂智品.呼吸机相关性肺炎的感染途径及病原菌分布调查分析[J].中国临床医生杂志,2018,46(6):681-684. 被引量：11
2杨再兴,熊玮.盐酸氨溴索辅助治疗对AECOPD合并呼吸衰竭患者血气指标与肺功能的影响[J].山西医药杂志,2018,47(4):428-431. 被引量：28
3王云霞,宓文珍,赵丽丽,周桂杰,李华.盐酸氨溴索应用剂量对COPD呼吸机相关肺部感染患者临床效果的影响[J].中华医院感染学杂志,2018,28(9):1338-1341. 被引量：46
4陈飞.盐酸氨溴索对呼吸机相关性肺炎患者CPIS评分及炎性因子表达影响[J].临床肺科杂志,2018,23(10):1808-1811. 被引量：15
5邓磊,李依.大剂量泵注盐酸氨溴索对呼吸机相关性肺炎患者感染控制及预后的影响[J].中国药房,2017,28(3):341-344. 被引量：32
6李静,刘政,马姣.慢性阻塞性肺疾病表型的研究进展[J].国际呼吸杂志,2016,36(19):1507-1511. 被引量：11

二级参考文献93

1Kamil F, Pinzon I, Foreman MG. Sex and race factors in early-onset COPD[J]. Curr Opin Pulm Med, 2013, 19 ( 2 ) : 140-144. DOI : 10. 1097/MCP. ObO13e32835d903b.
2Martinez CH, Raparla S, Plauschinat CA, et al. Gender differences in symptoms and care delivery for chronic obstructive pulmonary disease [ J ]. J Womens Health (Larchmt), 2012, 21 (12): 1267-1274. DOI: 10. 1089/jwh. 2012. 365O.
3Kilic H, Kokturk N, Sari G, et al. Do females behave differently in COPD exacerbation? [J]. Int J Chron Obstruct Pulmon Dis, 2015, 10 (10): 823-830. DOI: 10. 2147/COPD. $78952. eCollection 2015.
4Martinez FJ, Curtis JL, Sciurba F, et al. Sex differences in severe pulmonary emphysema [J]. Am J Respir Crit Care Med, 2007, 176 (3): 243-252. DOI: 10. l164/rccm. 200606- 828OC.
5Lo Tam Loi AT, Hoonhorst SJ, Franciosi L, et al. Acute and chronic inflammatory responses induced by smoking in individuals susceptible and non-susceptible to development of COPD: from specific disease phenotyping towards novel therapy. Protocol of a cross-sectional study [J]. BMJ Open, 2013, 3 (2). pii: e002178. DI)I: 10. 1136/bmjopen-2012- 002178.
6Higashimoto Y, Iwata T, Okada M, et al. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease[J]. Respir Med, 2009,103(8) : 1231-1238. DOI:10. 1016/j.rmed.2009.01.021.
7Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med, 2012, 185 (1): 44-52. DOI: 10. l164/rccm. 201106- 0992OC.
8Global Initiative for Chronic Obstructive Lung Disease: Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease, 2015 [EB/OL]. 2015 Global Initiative for Chronic Obstructive Lung Disease, Inc. www. gold copd. org.
9Global Initiative for Chronic Obstructive Lung Disease: Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease, 2014 [EB/OL]. 2014 Global Initiative for Chronic Obstructive Lung Disease, Inc. www. guide, medlive, cn.
10Tudoraehe E, Oancea C, Avram C, et al. Balance impairment and systemic inflammation in chronic obstructive pulmonary diseaseD3. Int J Chron Obstruct Pulmon Dis, 2015, 10 (10) : 1847-1852. DOI: 10. 2147/COPD. $89814.